01703-A: Enhancing Natural Anti-Tumor Immune Responses during Chemotherapy
Grant Status: Closed
Cancer is one of the leading causes of death in dogs. In dogs with cancer, suppressor T cells (Treg) prevent the elimination of cancer by suppressing killer immune cells. Dogs with cancer have significantly higher numbers of Treg when compared to healthy dogs because of stimuli secreted by the cancer. Increased numbers of Treg result in a decreased immune response to tumors and are associated with decreased survival in dogs with cancer. The goal of this study is to evaluate the effect of metronomic (daily, low dose) chlorambucil on Treg and killer immune cells using flow cytometry. The hypothesis of this study is that chlorambucil will significantly decrease the number of Treg and decrease the immune cell/Treg ratio. Confirmation of this hypothesis will prove that chlorambucil is an effective treatment; thus, potentially enhancing a dog's natural ability to mount an anti-tumor response.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.